NeurologyLive® Friday 5 — August 11, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, July 2023: Approvals, Clearances, and Requests

The FDA was busy in July 2023, making a number of decisions on potential new therapeutic agents including issuing a complete response letter, granting traditional approval, and clearing a clinical trial, among other actions.

2: Peer Exchange: Emerging Disease-Modifying Therapy Data in Multiple Sclerosis

Bruce Cree, MD, PhD, MAS, discusses new data presented at the 2023 European Academy of Neurology (EAN) congress on BTK inhibitors, such as Tolebrutinib, evobrutinib, renibrutinib, and fenibrutinib. Dr Cree also highlights important safety information and adverse events identified in these studies.

3: NeuroVoices: Bruce Bebo, PhD, on Expanding MS Research Through the Pathways to Cures Roadmap

The executive vice president of the National MS Society provided insight on the Pathways to Cures roadmap, a global initiative to stop multiple sclerosis, restore function, and end MS.

4: Botulinumtoxins in the Management of Movement Disorders: Laxman Bahroo, DO

The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]

5: Building a Greater Knowledge on Use of SMA Therapies: Thomas Crawford, MD

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the steps needed to improve treatment optimization in SMA, and the unanswered questions regarding the key biology of the disease.